SEARCH EISAI MEDICAL INFORMATION:

Product or Investigational agent*
BANZEL® (rufinamide)
DAYVIGO® (lemborexant) CIV
FYCOMPA® (perampanel) CIII
Lecanemab (BAN2401)
Lemborexant (E2006)
Lorcaserin (E2023)
E2027
E2814

*required fields

Please do not include these characters in your search (,),*,-

Please verify spelling of your keywords before submitting

Please provide an input in all required fields

Loading results ....
Please provide an input in all required fields

Please refine your search criteria or submit a medical inquiry.

Please note that Dayvigo is approved for those indications and dosages that appear in the enclosed Dayvigo Full Prescribing Information. The enclosed information and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of Dayvigo that have not been approved by the Food and Drug Administration.

The enclosed information is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Click here for Important Safety Information.

Please note that Fycompa is approved for those indications and dosages that appear in the enclosed Fycompa Full Prescribing Information. The enclosed information and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of Fycompa that have not been approved by the Food and Drug Administration.

The enclosed information is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Click here for Important Safety Information.

Please note that Banzel is approved for those indications and dosages that appear in the enclosed Banzel Full Prescribing Information. The enclosed information and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of Banzel that have not been approved by the Food and Drug Administration.

The enclosed information is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Click here for Important Safety Information.

Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information.

Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information.

Please refine your search criteria or submit a medical inquiry.

Search result(s) may include information that is not consistent with the product's Full Prescribing Information. Eisai does not recommend uses that are inconsistent with the Full Prescribing Information.


TO REPORT SUSPECTED ADVERSE EVENTS OR PRODUCT COMPLAINTS, PLEASE CALL 1-888-274-2378. YOU MAY ALSO REPORT SUSPECTED ADVERSE EVENTS TO THE FDA BY CALLING 1-800-FDA-1088 OR CLICK HERE